
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer
An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut
An interview with:
Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institute for Cancer Research, Beijing, China
Sarah Maxwell, Audio Journal of Oncology:
The idea of harnessing two different pathways of checkpoint inhibition simultaneously is very appealing for the treatment of high-risk gastric cancers. But a research team in China, proposed that, blocking both the PD-1 and CTLA-4 pathways, within a single bi-specific agent, as a component of initial therapy, was potentially a better way to do this than to use a combination of two individual checkpoint inhibitors.
At the 2024 American Association for Cancer Research annual meeting in San Diego, Jiafu Ji, from the Beijing Institute for Cancer Research, reported his group’s findings from the COMPASSION-15 trial, with 610 patients who had untreated, unresectable, HER2-negative, locally advanced or metastatic gastric cancer, using the bi-specific agent, cadonilimab, together with standard chemotherapy. After his talk he discussed with us the rational for this approach and the promising clinical findings:
Jiafu Ji, MD, PhD, DrPh, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, the Beijing Key Laboratory of Carcinogenesis and Translational Research, and the Gastrointestinal Cancer Center, Beijing Cancer Hospital, Beijing, China
IN: “Gastric cancer is a leading cause of death in China………
OUT………American Association for Cancer Research, I’m Peter Goodwin”
10:13 secs
AACR ABSTRACT
Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial
Next in AACR 2024
All 4 interviewsInterview 2 of 4

Exosome Liquid Biopsy for Earliest Pancreatic Cancer Detection
An interview with: Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California. SAN DIEGO—The prospect
Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?
SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma
BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca